Be a part of 15th World Nephrology Conference

Recent dialysis tech innovations, like portable devices and hemodiafiltration, improve kidney treatment. Bioartificial kidneys and nanotech offer hope for the future. The global home dialysis market, valued at $86.9 billion in 2023, is expected to grow to $105.1 billion by 2026, with a 6.4% CAGR.

Precision medicine in kidney disease tailors treatments based on genetic, environmental, and lifestyle factors. It identifies genetic markers, biomarkers, and risk profiles for personalized care. This approach enables targeted therapies, and early intervention, and empowers patients to manage their kidney health for better outcomes.

Biomarkers are vital in kidney disease for diagnosis, progress tracking, and treatment evaluation. Notably, albumin-to-creatinine ratio and kidney injury molecule-1 offer crucial insights. Genetic markers aid risk assessment, enabling precision medicine. The Renal Biomarkers Market is set to grow from USD 1.24 billion in 2023 to USD 1.77 billion by 2028, with a CAGR of 7.29%.

Immunotherapy in glomerular diseases targets immune responses causing kidney damage. Utilizing agents like monoclonal antibodies and corticosteroids, it shows promise in treating conditions like lupus nephritis and membranous nephropathy. The Global Glomerular Disease Therapeutics Market, valued at USD 12,590.4 million in 2023, is projected to reach USD 18,601.7 million by 2029, with an expected CAGR of 5%.

Exosome-based nephrology therapies hold the potential for kidney repair, inflammation reduction, and fibrosis treatment. Derived from cells like MSCs, they deliver bioactive molecules for tissue healing and immune regulation. Promising for AKI, glomerulonephritis, and CKD, the global market for exosome products is expected to reach $2.9 billion by 2030, with a 29.4% CAGR from 2021 to 2030.

Innovations in renal replacement therapies, including hemodialysis, peritoneal dialysis, and kidney transplantation, are significantly improving patient quality of life and survival rates. Recent strides in kidney transplantation encompass expanded donor options, potent immunosuppressive drugs, and refined surgical methods, personalized matching, and advanced organ preservation techniques. This progress contributes to improved outcomes. The global kidney transplant market is forecasted to increase from $5.49 billion in 2023 to $5.80 billion in 2024, with a 5.7% CAGR.

Telemedicine in nephrology employs technology for remote kidney-related care, enabling virtual consultations and monitoring of vital signs, especially vital for chronic conditions. It enhances accessibility, is crucial for rural or underserved areas, and gained prominence during the COVID-19 pandemic. The global telemedicine market is projected to reach $131.75 billion in 2024 with a 27.8% CAGR.

Nutritional management in kidney disease involves customizing diets, regulating protein, sodium, potassium, and phosphorus intake, and monitoring fluid balance. Dialysis may require specific dietary adjustments. Registered dietitians play a crucial role in crafting personalized nutrition plans. The global chronic kidney disease treatment market was valued at $32 billion in 2022, projected to reach $47.9 billion by 2032, with a 4% CAGR from 2023 to 2032.

Interventional nephrology employs minimally invasive procedures for diagnosing and treating kidney conditions, like catheter insertion, kidney biopsies, and dialysis access management. It significantly enhances patient outcomes and quality of life. The global interventional radiology imaging market is projected to grow from USD 16.99 Billion in 2023 to USD 23.50 Billion by 2031, with a 6.7% CAGR from 2023 to 2031.

Kidney organoids, derived from stem cells, provide insights into kidney development, disease modeling, and drug testing. Tissue engineering, using cells, scaffolds, and bioactive molecules, aims to create functional kidney tissue for transplantation and research. Challenges include vascularization and immunogenicity. The organoids market is projected to reach $12.2 billion by 2030, with a 21.9% CAGR.

Pediatric nephrology focuses on diagnosing and managing kidney-related conditions in children, covering congenital anomalies, glomerular disorders, hypertension, and kidney diseases. Treatment includes medication, dialysis, or transplantation. Pediatric nephrologists collaborate with specialists, providing specialized, long-term care tailored to young patients. The pediatric nephrology market is projected to grow from $23.2 billion in 2020 to $35.8 billion by 2027.

Global health aims to enhance well-being worldwide. Kidney disease poses a major concern, with increasing prevalence. Challenges include limited access to care, especially in low-resource areas, and addressing risk factors like hypertension and diabetes. Strategies involve prevention, early detection, and ensuring equal treatment access. The market was valued at USD 96.72 billion in 2021, projected to reach USD 148.43 billion by 2029.

Diabetic nephropathy is a serious complication of diabetes that affects the kidneys. It is characterized by damage to the small blood vessels in the kidneys, leading to impaired kidney function over time.Global Diabetic Nephropathy Market size was valued at USD 1.9 billion in 2021 and is poised to grow from USD 2.01 billion in 2022 to USD 3.21 billion by 2030, growing at a CAGR of 6% in the forecast period (2023-2030).

Cardio-renal syndromes (CRS) represent a complex interplay between the heart and kidneys, where dysfunction in one organ can induce dysfunction in the other. Understanding CRS is crucial for managing patients with heart and kidney diseases, as these conditions often coexist and exacerbate each other.The overall CAGR for the CRS market is expected to be in the range of 6-7% from 2021 to 2024, reflecting strong demand and continuous advancements in medical technology and patient care.